Evidence map›Paper›PMID 36817507›Full record

ArticleOncoTargets and therapy2023

Secondary Sinonasal Collision Tumor of Papillary Squamous Cell Carcinoma and Small Cell Neuroendocrine Carcinoma After Nasopharyngeal Carcinoma Radiotherapy: A Case Report and Literature Review of Sinonasal Collision Carcinomas.

Hao Tang, Lina Wang, Wenfeng Xu, Yujuan Xu, Xianyun Li, Deyu Guo

Abstract readCase Reports
In one paragraph

Article in OncoTargets and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hao TangDepartment of Pathology, Guiqian International General Hospital, Guiyang, Guizhou, People's Republic of China.ORCID 0000-0001-7646-2154
Lina WangDepartment of Pathology, Guiqian International General Hospital, Guiyang, Guizhou, People's Republic of China.
Wenfeng XuDepartment of Pathology, Guiqian International General Hospital, Guiyang, Guizhou, People's Republic of China.ORCID 0000-0003-0896-4309
Yujuan XuDepartment of Pathology, Guiqian International General Hospital, Guiyang, Guizhou, People's Republic of China.
Xianyun LiDepartment of Pathology, Guiqian International General Hospital, Guiyang, Guizhou, People's Republic of China.
Deyu GuoDepartment of Pathology, Guiqian International General Hospital, Guiyang, Guizhou, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the head and neck region, small cell neuroendocrine carcinoma (SmNEC) is extraordinary infrequent. Collision malignancy is also a rare entity in the nasal cavity, with merely sporadic 6 case reports on primary collision tumor associated with neuroendocrine carcinoma. The development of a secondary SmNEC within the previous radiation field had uncommonly been described, and there was no report on secondary sinonasal collision carcinoma with SmNEC component as a side reaction of nasopharyngeal carcinoma (NPC) radiotherapy. In light of the rarity of these neoplasms, we presented a case of a sinonasal collision carcinoma of papillary squamous cell carcinoma (PSCC) and SmNEC after NPC radiotherapy. To our knowledge, it may be the first case of a secondary coexistence of two malignancies synchronously in the nasal cavity after NPC treatment. Recognizing this peculiar kind of collision tumor associated SmNEC could promote our understanding of this entity and hence propose optimal treatment strategies.

Indexed as

collision tumornasopharyngeal carcinomapapillary squamous cell carcinomasmall cell neuroendocrine carcinoma

Identifiers

PMID36817507
PMCPMC9930577

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.